On September 5th, the 2023 China International Intelligent Industry Expo Pharmaceutical Industry Digitalization Summit was held at the Lijia Smart Hall in Liangjiang New Area. Experts and scholars attending the summit discussed and exchanged ideas on the digitalization of the pharmaceutical industry.

The summit, with the theme of "Gathering Smart Innovation and Leading Industrial Development", has set up a main venue and three parallel sub venues, aiming to lead the policy and technological development trends of the pharmaceutical industry, promote the integration of the pharmaceutical industry with the digital economy, and facilitate the leapfrog development of the pharmaceutical industry.

"After decades of development, China has made great progress in both new drug discovery and drug manufacturing, but most of its achievements are based on simple imitation and tracking innovation." Ma Dawei, academician of the CAS Member and researcher of the Chinese Academy of Sciences Shanghai Institute of Organic Chemistry, believes that source innovation is to open a new path in no man's land, which is totally different from the underlying logic of tracking along others' path. In addition to being mentally prepared to face failure, it is more crucial to carefully plan for possible success.

Wang Xuegong, Vice President of the China Pharmaceutical Enterprise Management Association, delivered a keynote speech on the theme of "Development Situation and Digital Transformation of the Pharmaceutical Industry". He stated that digitization is the direction for high-quality development of the pharmaceutical industry and also a means for enterprises to cope with competition. To avoid falling into misunderstandings in enterprise digitalization, enterprise digitalization projects need to combine their own process foundation, management foundation, business characteristics, and various conditions, adopt appropriate strategies and paths, and prioritize optimizing management processes. At the same time, the launch of information systems is not the end of digital factory construction, but should be regarded as the beginning of enterprise digital transformation.

Chen Ming, Director of the Pharmaceutical Development Department of the Industrial and Information Consumer Goods Industry Department, brings the "Report on the Development Situation and Tasks of China's Pharmaceutical Industry". He said that since the 14th Five Year Plan, the overall operation of China's pharmaceutical industry has been stable. Domestic innovative drugs and innovative medical devices have been continuously approved for listing, and many products have achieved overseas listing. It can be said that the industry's innovation capability has significantly improved.

How difficult is it to develop a new drug? He Ruyi, Chief Medical Scientist of Rongchang Biotechnology and Chief Scientist of Guotou Innovation Healthcare, believes that AI has the potential to overturn the existing paradigm of drug development. He said that AI pharmaceuticals, based on pharmaceutical big data, use AI technologies such as machine learning and deep learning to replace a large number of experiments and quickly analyze drug structures, efficacy, etc., in order to shorten the trial period, save costs, promote new drug discovery, and improve trial efficiency. AI has become an important tool for international pharmaceutical giants, with over 700 AI pharmaceutical companies worldwide and nearly 80 AI startups in China.

At the summit that day, the "2023 Blue Book on the Digital Development of China's Pharmaceutical Industry" was also released, which systematically analyzed the current status of the digital transformation of China's pharmaceutical industry, sorted out the development of the industry and technology, and analyzed the driving factors behind the transformation and development.

Prev：Intelligent pharmaceuticals | Are there any intelligent systems in the equipment layer and control l

Next：没有了！